跳至主要内容
临床试验/NCT06522334
NCT06522334招募中不适用

Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria

Ludwig Boltzmann Institute for Lung Health5 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2024年2月28日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
400
试验地点
5
主要终点
Mortality

研究概览

简要总结

The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death.

There are no additional interventions regarding this registry.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of interstitial lung disease
  • written informed consent

排除标准

  • to not comprehend and rightfully judge participation

结局指标

主要结局

Mortality

时间窗: 10 years

Mortality caused by interstitial lung disease

Loss of lung function

时间窗: 2 years

FVC and DLCO loss within 24 months

次要结局

  • Prevalence(10 years)
  • Response to drugs(10 years)

研究者

发起方
Ludwig Boltzmann Institute for Lung Health
申办方类型
Other
责任方
Principal Investigator
主要研究者

Robab Breyer-Kohansal

Head of Department for Internal Medicine and Pneumology Clinic Hietzing

Ludwig Boltzmann Institute for Lung Health

研究点 (5)

Loading locations...

相似试验